{"name":"NeurogesX","slug":"neurogesx","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":11503000,"revenueGrowth":39.2,"grossMargin":0,"rdSpend":13566000,"netIncome":-49545000,"cash":39227000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2011"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NGX-4010","genericName":"NGX-4010","slug":"ngx-4010","indication":"Postherpetic neuralgia (PHN)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"NGX-4010, 8% capsaicin patch","genericName":"NGX-4010, 8% capsaicin patch","slug":"ngx-4010-8-capsaicin-patch","indication":"Postherpetic neuralgia","status":"phase_3"}]}],"pipeline":[{"name":"NGX-4010","genericName":"NGX-4010","slug":"ngx-4010","phase":"phase_3","mechanism":"NGX-4010 is a topical capsaicin patch that desensitizes nociceptors (pain-sensing nerve fibers) by depleting substance P, reducing localized pain transmission.","indications":["Postherpetic neuralgia (PHN)","Peripheral neuropathic pain"],"catalyst":""},{"name":"NGX-4010, 8% capsaicin patch","genericName":"NGX-4010, 8% capsaicin patch","slug":"ngx-4010-8-capsaicin-patch","phase":"phase_3","mechanism":"NGX-4010, an 8% capsaicin patch, works by activating TRPV1 receptors to reduce pain.","indications":["Postherpetic neuralgia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNdGM5NW1Zc3A0MU5GNFYyRXcwQmFGT0Y0SEo0M0UxSmRaY0tsWWh1MVZJcGtGXzR0ZFp6VE93cXIxbmF1MmhMOVprWGVKQTF2NnNrQmJtZVhKbWFXQTBBMEw3OTd2NzVHaDB6Wl9Dc08xMWItMzZod0NqNmpPY2VGRkJwWQ?oc=5","date":"2016-12-13","type":"pipeline","source":"BioPharma Dive","summary":"Grünenthal picks up rights to pain patch from Astellas - BioPharma Dive","headline":"Grünenthal picks up rights to pain patch from Astellas","sentiment":"neutral"},{"date":"2016-01-07","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SC 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"date":"2015-09-17","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SC 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"date":"2015-02-10","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SCHEDULE 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1uN2R3LUxyenhPQjZqc0RvTmZEaVNwNmQ3dzB2UHBzVmx1NEs0RjRUcHhXcWxHZk9VcnN0NHF2MWlLRFFZY3BFTXVWa244VUNzZjZXakJubW9CU2stSHFWTVZMcTlhYTZJZ1hqUXplZG9EQQ?oc=5","date":"2014-11-28","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"30 Top VC Firms for Biotechs - Genetic Engineering and Biotechnology News","headline":"30 Top VC Firms for Biotechs","sentiment":"neutral"},{"date":"2013-07-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2013-06-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2013-04-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2013-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2013-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":11503000,"revenuePeriod":"2011-12-31","revenueHistory":[{"value":11503000,"period":"2011-12-31"},{"value":8266000,"period":"2010-12-31"},{"value":2006000,"period":"2009-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":13566000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-49545000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":39227000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}